UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 375

Sortiert nach

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

Annals of oncology, 2015-08, Vol.26 (8), p.1722-1728

2015

Link zum Volltext

Verfügbarkeit prüfen

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

The European respiratory journal, 2011-03, Vol.37 (3), p.624-631

2011

Link zum Volltext

Verfügbarkeit prüfen

System analysis and test-bed for an atmosphere-breathing electric propulsion system using an inductive plasma thruster

Acta astronautica, 2018-06, Vol.147, p.114-126

2018

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

Annals of oncology, 2015-01, Vol.26 (1), p.149-156

2015

Link zum Volltext

Verfügbarkeit prüfen

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

British journal of cancer, 2010-08, Vol.103 (4), p.581-589

2010

Link zum Volltext

Verfügbarkeit prüfen

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Clinical & translational oncology, 2015-12, Vol.17 (12), p.1020-1029

2015

Link zum Volltext

Verfügbarkeit prüfen

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

Annals of oncology, 2019-03, Vol.30 (3), p.439-446

2019

Link zum Volltext

Verfügbarkeit prüfen

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours

European journal of cancer (1990), 2015-07, Vol.51 (11), p.1371-1380

2015

Link zum Volltext

Verfügbarkeit prüfen

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

Critical reviews in oncology/hematology, 2011-01, Vol.77 (1), p.78-84

2011

Link zum Volltext

Verfügbarkeit prüfen

Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases

Annals of oncology, 2009-01, Vol.20 (1), p.91-97

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

Annals of oncology, 2006-03, Vol.17 (3), p.467-472

2006

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

Annals of oncology, 2006-04, Vol.17 (4), p.668-675

2006

Link zum Volltext

Verfügbarkeit prüfen

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group

Annals of oncology, 2003-06, Vol.14 (6), p.833-842

2003

Link zum Volltext

Verfügbarkeit prüfen

Recent catalysis measurements at IRS

Advances in space research, 2015-08, Vol.56 (4), p.742-765

2015

Link zum Volltext

Verfügbarkeit prüfen

3074 Platinum-pemetrexed palliative chemotherapy in malignant pleural mesothelioma from Spanish BEMME database The Spanish Lung Cancer Group (SLCG)

European journal of cancer (1990), 2015-09, Vol.51, p.S622-S622

2015

Link zum Volltext

Verfügbarkeit prüfen

2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)

European journal of cancer (1990), 2015-09, Vol.51, p.S374-S375

2015

Link zum Volltext

Verfügbarkeit prüfen

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

BMC cancer, 2019-06, Vol.19 (1), p.533-9, Article 533

2019

Link zum Volltext

Verfügbarkeit prüfen

Pharmacogenomics and gemcitabine

Annals of oncology, 2006-05, Vol.17 (suppl-5), p.v13-v16

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02

Cancer chemotherapy and pharmacology, 2015-02, Vol.75 (2), p.319-324

2015

Link zum Volltext

Verfügbarkeit prüfen

Trichomegaly following treatment with gefitinib (ZD1839)

British journal of dermatology (1951), 2004-11, Vol.151 (5), p.1111-1112

2004

Link zum Volltext

Verfügbarkeit prüfen

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer

Cancer chemotherapy and pharmacology, 2012-12, Vol.70 (6), p.883-890

2012

Link zum Volltext

Verfügbarkeit prüfen

Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer

Clinical cancer research, 2000-06, Vol.6 (6), p.2356-2362

2000

Link zum Volltext

Verfügbarkeit prüfen

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Clinical & translational oncology, 2017-02, Vol.19 (2), p.219-226

2017

Link zum Volltext

Verfügbarkeit prüfen

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

Annals of oncology, 2018-02, Vol.29 (2), p.439-444

2018

Link zum Volltext

Verfügbarkeit prüfen

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

Clinical & translational oncology, 2013-09, Vol.15 (9), p.705-711

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 375

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(360)
Mit Volltextzugriff
(356)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(102)
Life Sciences & Biomedicine
(94)
Humans
(74)
Female
(55)
Middle Aged
(55)
Male
(52)
Oncology
(51)
Aged
(45)
Biological And Medical Sciences
(45)
Adult
(39)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(31)
Marine
(31)
Marine & Freshwater Biology
(31)
Medical Sciences
(31)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(24)
Chemotherapy
(24)
Hematology, Oncology And Palliative Medicine
(24)
Treatment Outcome
(24)
Lung Neoplasms - Drug Therapy
(23)
Pharmacology. Drug Treatments
(22)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

System analysis and test-bed for an atmosphere-breathing electric propulsion system using an inductive plasma thruster

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours

First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group

Recent catalysis measurements at IRS

3074 Platinum-pemetrexed palliative chemotherapy in malignant pleural mesothelioma from Spanish BEMME database The Spanish Lung Cancer Group (SLCG)

2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Pharmacogenomics and gemcitabine

Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02

Trichomegaly following treatment with gefitinib (ZD1839)

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer

Circulating HER2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer

Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

Suchergebnisse filtern